Archive for April, 2014

(ADMS) Data Update On ADS-5102 At American Academy Of Neurology Annual Meeting

Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102

EMERYVILLE, Calif., April 30, 2014  — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson’s disease treatment. The data, from Adamas’ Phase 2/3 EASED study, included assessments of patients receiving ADS-5102 using a metric called the Clinician’s Global Impression of Change (CGI-C). The clinicians were asked to assess their impression of the change in a subject’s clinical status related to overall Parkinson’s disease, including LID. CGI-C is a tool to evaluate a patient’s response over time and is routinely used for a number of diseases, including Parkinson’s disease.

At the 340 mg dose level there was a statistically significant improvement in overall Parkinson’s disease clinical status, including LID, versus placebo as measured by physicians using the CGI-C (p=0.0036).

“These clinician-reported data add to the totality of information we have generated on ADS-5102 and reflect the consistent improvements observed using a number of different outcome measures,” said Natalie McClure, Ph.D., Adamas’ Senior Vice President of Product Development. “The Phase 2/3 EASED study met its primary endpoint, and we have selected the dose for future development. We are now advancing ADS-5102 into a Phase 3 study, which is anticipated to start later this year.”

Phase 2/3 Trial Design – EASED Study
The Phase 2/3 EASED trial was a randomized, double-blind, placebo-controlled, parallel-group study conducted at sites throughout the United States. Eighty-three Parkinson’s disease patients with troublesome LID were randomized to placebo or one of three doses of ADS-5102 (260 mg, 340 mg, 420 mg), dosed once nightly for eight weeks. The primary outcome measure was the change from baseline to week eight in the Unified Dyskinesia Rating Scale (UDysRS) total score. Secondary outcome measures were: change from baseline in 24-hour patient diaries, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Clinician’s Global Impression of Change (CGI-C). The study met its primary endpoint demonstrating a statistically significant reduction in LID as measured by the change in UDysRS total score versus placebo. In addition, ADS-5102 was generally well tolerated and reported adverse events were consistent with Parkinson’s disease and the known amantadine safety profile.

About ADS-5102
ADS-5102 is a controlled-release version of the approved drug amantadine. Adamas is developing ADS-5102 initially for treatment of LID, a movement disorder that frequently occurs in patients with Parkinson’s disease after long-term treatment with levodopa, the most widely-used drug for Parkinson’s disease. Many individuals with late-stage Parkinson’s disease suffer from LID, and there are no approved treatments for this disorder. Patients with LID suffer from involuntary movements and reduced control over voluntary movements.

Adamas believes that ADS-5102 may address many of the limitations of immediate-release amantadine by allowing higher daily doses of amantadine to be administered once-nightly without a significant increase in side effects. In the EASED study, in patients taking ADS-5102, the amantadine plasma concentration achieved in the early morning through mid-day was approximately two-times that reached following administration of immediate-release amantadine, providing symptomatic relief to patients as they engaged in their daily activities. Further, the lower concentrations occurred in the evening, reducing the potential negative impact of amantadine’s sleep-related side effects.

Phase 3 Study Planned
The upcoming Phase 3 study will be a multi-center, randomized, double-blind, placebo-controlled, two-arm parallel group trial. Its primary objective will be to confirm the efficacy of a once-nightly 340 mg dose of ADS-5102 for the treatment of LID in subjects with Parkinson’s disease. The secondary objective will be to evaluate the safety and tolerability of ADS-5102 in the study population.

About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. Adamas achieves this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson’s disease known as levodopa-induced dyskinesia and as a treatment for chronic behavioral symptoms associated with traumatic brain injury.

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements include, but are not limited to, statements regarding the timing of Adamas’ second Phase 3 study for ADS-5102. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation: the accuracy of Adamas’ estimates regarding its ability to initiate and/or complete its clinical trials; the success of Adamas’ clinical trials and the demonstrated efficacy of Adamas’ product candidates thereunder; regulatory developments in the United States and foreign countries; Adamas’ ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Adamas’ most recent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adamas undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Wednesday, April 30th, 2014 Uncategorized Comments Off on (ADMS) Data Update On ADS-5102 At American Academy Of Neurology Annual Meeting

(UBIC) Lit i View ANALYZER Available in U.S. June 1

ANALYZER Combines AI-Based Predictive Coding With UBIC’s Central Linkage Capabilities to Create Powerful Forensic Tool for U.S. Investigative & Law Enforcement Agencies

TOKYO, April 30, 2014  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today the commercial introduction of Lit i View® ANALYZER, a digital forensic tool designed specifically to help U.S. investigative and law enforcement agencies. UBIC will introduce this powerful tool in the U.S. on June 1.

Optimized to carryout specialized forensic analyses, Lit i View® ANALYZER is built on UBIC’s cutting-edge, in-house developed technologies used in Lit i View® XAMINER, a next-generation forensic software program released in September.

“ANALYZER sets a new and highly effective standard in digital forensic capability that was simply unavailable to U.S. investigative agencies until now,” UBIC Chairman and Chief Executive Officer Masahiro Morimoto said. “We believe UBIC is the first company to make this type of integrated digital-forensics capability available in the U.S. market. And, based on our successful track record in the field of forensic investigation in Japan, we believe that Lit i View® ANALYZER will prove popular among U.S. investigative and law enforcement agencies.”

Lit i View® ANALYZER combines the power of UBIC’s proven predictive-coding engine, which can quickly and accurately cut through vast stores of data to find very specific information without human intervention, with UBIC’s Central Linkage technology that maps relationships to visualize the process of human communications within and between organizations.

“We fully expect Lit i View® ANALYZER to be regarded positively by investigative divisions within the U.S. Justice Department as well as those within state and county-based police organizations,” Mr. Morimoto said.

Optimized to Serve Investigative Agencies in the U.S.

Forensics refers to a set of scientific investigative techniques and technologies used to preserve, investigate and analyze electronic data and conduct analysis and information-gathering activity regarding tampering and destruction of electronic records. As a result of the advance of IT, much of the evidence investigated in litigation cases exists in electronic form, requiring digital forensic activities, including restoring lost or deleted mobile phone records and collecting and analyzing records of email communications for evidence of wrongdoing. All these activities constitute the science of digital forensics.

“In the global market for digital forensic tools, products available from two major U.S. vendors have become the de facto standard and, until now, it has been all but impossible for a Japanese vendor like UBIC to sell its data analysis software to U.S. investigative and law enforcement agencies,” UBIC North America, Inc.’s Chief Global Risk Officer Paul Starrett said. “To crack open the market, UBIC has developed a product featuring unique functions that set it apart from the dominant U.S. vendors’ popular tools. Using UBIC’s Lit i View® ANALYZER to complement existing forensic tools, U.S. agencies will be able to maximize their investigative powers.”

UBIC’s Lit i View® ANALYZER is equipped with the most advanced technologies developed by UBIC, which were first employed in Lit i View® XAMINER, including artificial intelligence (AI)-based predictive coding and its Central Linkage software tool that visualizes human communication by creating relationship mapping.

AI-Based Predictive Coding

AI-based predictive coding realizes an advanced search function that automatically classifies document files according to relevance, evaluated on the basis of feedback from the processing of sample data. An exhaustive review of documents using this function makes it possible to find relevant data (evidence materials) that may be overlooked by keyword-based search or by human reviewers. The AI-based software program has a massive document review capacity, 3,000 times the capacity of a human reviewer. Forensic tools equipped with an advanced function like this are not available from any other company in the world.

Central Linkage Visualizes Human Communications

This is a function used to visualize human communications by analyzing email exchanges between individuals in a communication network. In addition to mapping out the relationship between individuals, Central Linkage is capable of visualizing communication networks between organizations. This feature is capable of measuring the “Betweenness Centrality” of nodes in the communication network and can be integrated with Predictive Coding to extract email exchanges pertaining to specific topics.

This feature has a proven track record of identifying relevant individuals that were missed by standard forensic procedures. Since this tool provides a more efficient and holistic approach in analyzing large volumes of data, investigators can take comfort in knowing that more of the relevant individuals are being identified in the earlier stages of the investigation with considerably less effort.

Time constraints are a significant challenge for criminal investigation, whether in Japan or in the United States. After making an arrest, police must gather evidence and decide within a certain period of time (48 hours in Japan) whether to release or send the suspect to a prosecutor. However, evidence gathering can be a highly time-consuming process, as the data stored in just one personal computer is equivalent in volume to several truckloads of paper. Leveraging advanced IT to quickly and accurately cull down data and find the needles of evidence in the electronic haystack is a job that UBIC’s technologies accomplish.

“Forensic tools offered by the two major U.S. vendors are good at finding evidence through an intensive search from among a narrow set of data,” Mr. Starrett said. “In contrast, Lit i View® ANALYZER excels in exhaustively combing a comprehensive set of data, including email communications in a variety of languages.

“It is also better suited to organized crime probes as it is superior in quickly creating correlation diagrams by identifying relevant texts from among records of email communications. These features have won praise from Japanese investigative and law enforcement agencies that have employed Lit i View® XAMINER.”

About UBIC

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) is a leading provider of e-discovery and digital forensic services for Asia and the world. UBIC has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of e-discovery innovation, UBIC’s proprietary Lit i View® platform is moving the industry from “fact discovery” to “future discovery” by allowing clients to analyze e-mail messages and digital communications found in big data to reveal patterns in human thought and behavior.

For more information about UBIC, contact us info@ubicna.com or visit http://www.ubicna.com

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: Sasha Hefler
         sasha_hefler@ubica.com
Wednesday, April 30th, 2014 Uncategorized Comments Off on (UBIC) Lit i View ANALYZER Available in U.S. June 1

(FXEN) Reports Estimated 24 Mmcf/d Production Rate for Tuchola Field

SALT LAKE CITY, April 30, 2014  — FX Energy, Inc. (NASDAQ: FXEN) today reported estimated production rates based on the production test on the Tuchola-4K well originally reported on April 21, 2014. The calculated absolute open flow rate for the Tuchola-4K well was 117 million cubic feet per day (Mmcf/d), compared to the calculated absolute open flow rate for the Tuchola-3K well of 98 Mmcf/d.  The estimated initial stabilized production rate for the two wells combined is expected to be approximately 24 Mmcf/d when production starts. The Company plans to complete the Tuchola-4K and run another production test, after which it expects to release internal estimates of recoverable reserves and gas composition for the field.

“These projected flow rates are impressive,” said Andy Pierce, VP of Operations, “significantly better than we had hoped. We have very good porosity in a highly fractured dolomite; this combination provides tremendous flow rates. The Edge exploration play looks very promising, though we need to remain cautious as we are in the early stages of understanding this opportunity.”

The Tuchola-4K well currently is at 3,062 meters drilling toward a middle-Devonian target horizon at a depth of approximately 3,400 meters. The Tuchola-4K is an appraisal of the original discovery announced in May 2013 and serves as “proof of concept” of the Company’s Edge exploration play. The Company expects to start drilling another well in the area later this year.

The Tuchola wells are located in the Company’s 730,000-acre Edge License in north central Poland. FX Energy operates and holds 100% working interest.

About FX Energy
FX Energy is an independent oil and gas exploration and production company with production in the US and Poland. The Company’s main exploration and production activity is focused on Poland’s Permian Basin where the gas-bearing Rotliegend sandstone is a direct analog to the Southern Gas Basin offshore England. The Company trades on the NASDAQ Global Market under the symbol FXEN. Website www.fxenergy.com

FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements. Forward-looking statements are not guarantees. For example, exploration, drilling, development, construction or other projects or operations may be subject to the successful completion of technical work; environmental, governmental or partner approvals; equipment availability, or other things that are or may be beyond the control of the Company. Operations that are anticipated, planned or scheduled may be changed, delayed, take longer than expected, fail to accomplish intended results, or not take place at all.

In carrying out exploration it is necessary to identify and evaluate risks and potential rewards. This identification and evaluation is informed by science but remains inherently uncertain. Subsurface features that appear to be possible traps may not exist at all, may be smaller than interpreted, may not contain hydrocarbons, may not contain the quantity or quality estimated, or may have reservoir conditions that do not allow adequate recovery to render a discovery commercial or profitable. Forward-looking statements about the size, potential or likelihood of discovery with respect to exploration targets are certainly not guarantees of discovery or of the actual presence or recoverability of hydrocarbons, or of the ability to produce in commercial or profitable quantities. Estimates of potential typically do not take into account all the risks of drilling and completion nor do they take into account the fact that hydrocarbon volumes are never 100% recoverable. Such estimates are part of the complex process of trying to measure and evaluate risk and reward in an uncertain industry.

Forward-looking statements are subject to risks and uncertainties outside FX Energy’s control. Actual events or results may differ materially from the forward-looking statements. For a discussion of additional contingencies and uncertainties to which information respecting future events is subject, see FX Energy’s SEC reports or visit FX Energy’s website at www.fxenergy.com.

Wednesday, April 30th, 2014 Uncategorized Comments Off on (FXEN) Reports Estimated 24 Mmcf/d Production Rate for Tuchola Field

(ISR) Cancer Fighting Cesium-131 Isotope Published Report Shows Significant Results

84.4% Local Control With 12 Month Median Follow-Up, Exceeding Other Previously Published Rates of Between 33% and 63%

RICHLAND, WA–(Apr 30, 2014) – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing improved results using IsoRay’s Cesium-131 seeds in the treatment of gynecologic cancer.

IsoRay CEO Dwight Babcock commented, “We are very excited to have our Cesium-131 isotope seeds chosen for use in the treatment of gynecologic cancers. We believe our marketing is most successful by teaming up with medical industry thought leaders as they seek better solutions and outcomes for their patients. As we continue to develop our product offerings internally with support from industry leaders, our message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients.”

Dr. Marcus Randall MD, FACR of Markey Cancer Center, University of Kentucky, a co-author of the publication, stated: “Cesium-131 has totally replaced Au-198 as the isotope of choice for permanent gynecologic implants, and we are very happy with the results and the radiation safety profile”. To review the entire published research report please follow the link provided here: http://download.journals.elsevierhealth.com/pdfs/journals/0090-8258/PIIS0090825814001334.pdf.

Babcock said, “Published studies are the final step to commercialization as leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer. As with this latest publication on gynecological cancers, I believe Cesium-131 is now a proven solution that can meet patient needs.”

IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability and the ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

Contact:

IsoRay Medical
Info@Isoray.com
(509) 375-1202

Or

Worldwide Financial
Info@wwfinancial.com
(954) 360-9998

Wednesday, April 30th, 2014 Uncategorized Comments Off on (ISR) Cancer Fighting Cesium-131 Isotope Published Report Shows Significant Results

(AVNR) Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026

ALISO VIEJO, Calif., April 30, 2014, 2014  — Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company’s patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications (‘ANDAs’) for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect.

Following a six day bench trial in the District of Delaware, Judge Leonard P. Stark issued a ruling upholding the validity of the patents covering NUEDEXTA (US Patent Nos. RE38,115, 7,659,282 (the “‘282 patent”) and 8,227,484 (the “‘484 patent”), and holding that the proposed ANDA formulations infringe the claims of the ‘282 patent and ‘484 patent.

“We are very pleased with the Court’s decision, as it confirms our continued belief in the strength of the patents covering NUEDEXTA,” said Keith A. Katkin, president and chief executive officer of Avanir. “Our focus remains on making NUEDEXTA available to patients suffering from the debilitating condition of PBA. This decision provides twelve-plus years of market exclusivity for NUEDEXTA.”

NUEDEXTA remains the only FDA-approved product for the treatment of pseudobulbar affect.

About NUEDEXTA
NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA Important Safety Information
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer’s disease and other dementias.

NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at www.NUEDEXTA.com.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® and NUEDEXTA® are trademarks or registered trademarks of Avanir Pharmaceuticals, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir’s plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with : the difficulty in predicting the timing and outcome of an appeal of the Court’s decision; whether any other companies will submit ANDAs for generic versions of NUEDEXTA; Avanir’s operating performance and financial position; the market demand for and acceptance of Avanir’s products domestically and internationally; research, development and commercialization of new products domestically and internationally; obtaining additional indications; obtaining and maintaining regulatory approvals domestically and internationally; and other risks detailed from time to time in the Company’s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission.  These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Wednesday, April 30th, 2014 Uncategorized Comments Off on (AVNR) Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026

(VNRX) Announces First Published Data in Anticancer Research Journal

The Preliminary Data, Which Demonstrated High Detection Rates for Colorectal Cancer, Was the First to Be Publicly Shared by the Company Last Year

NAMUR, BELGIUM–(Apr 30, 2014) – VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces that preliminary data from University Hospital Bonn, Germany, has been published online in the leading peer-reviewed journal, Anticancer Research. The data, first presented at CNAPS (Circulating Nucleic Acids in Plasma and Serum) congress last year, shows VolitionRx’s single proprietary NuQ®-5mc assay detects 75% of colorectal cancers with 70% specificity. Since then, VolitionRx has achieved even better detection rates by combining its assays. The full article, “Novel Serum Nucleosomics Biomarkers for the Detection of Colorectal Cancer” is available on VolitionRx’s website at http://volitionrx.com/technologies-abstracts-papers-posters.html, or at Anticancer Research’s website at http://ar.iiarjournals.org/content/34/5/2357.abstract?etoc.

The independent trial at University Hospital Bonn was coordinated by Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology. Using VolitionRx’s NuQ® assay, his team tested 90 patient samples and found significantly lower levels of nucleosomes containing methylated DNA in the blood of patients with colorectal cancer compared to healthy samples, and later validated the results in a second set of 113 people.

Last year, VolitionRx proved that it could further improve detection rates by searching for more than one nucleosome biomarker and effectively creating a ‘panel’ test. Using samples from CHU Dinant Godinne/UCL Namur Hospital in Belgium, the team detected 85% of colorectal cancer with 85% specificity when combining two NuQ assays.

“It is encouraging to see data supporting the use of our blood tests for the detection of colorectal cancer being published for the very first time; it is a pivotal moment for us. Dr. Holdenrieder’s study was the first to acknowledge the potential of our NuQ tests,” said Jake Micallef, Chief Scientific Officer of VolitionRx. “It’s promising that similar results have been found independently from our own trials as we look to bring the test to market.”

Dr. Holdenrieder comments, “We are very excited to have our study published in such a prestigious journal. Since this study, we have seen more and more data confirming our findings and I am eager to ensure that this bank of research continues to grow so that patients can gain access to this rapid diagnostic tool as soon as possible. As such, I recently agreed to lead a performance evaluation study for VolitionRx’s CE mark application process.”

Other clinical trials assessing the effectiveness of VolitionRx’s assays include:

  • A 4,800 patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
  • A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany
  • A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream — an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx’s website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Safe Harbor Statement

Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Media Contacts

Charlotte Reynolds
VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com

Jon Falcone
Racepoint Global
Phone: +44 (0) 208 811 2121
Email: Jon.Falcone@racepointglobal.com

Investor Contacts
Kirin M. Smith
Proactive Capital
E: mksmith@proactivecapital.com
T: +1 646 863 6519

Wednesday, April 30th, 2014 Uncategorized Comments Off on (VNRX) Announces First Published Data in Anticancer Research Journal

(MDXG) Issued Four New U.S. Patents For Placental Tissue Allografts

Company Amends its Patent Infringement Lawsuit to Include Two Additional Patents

MARIETTA, Ga., April 29, 2014  — MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four newly issued patents related to the Company’s tissue allografts derived from the placenta.

On April 22, 2014, the U.S. Patent and Trademark Office awarded MiMedx U.S. Patent Numbers 8,703,206 and 8,703,207, both entitled “Placental Tissue Grafts.” On April 29, 2014, the U.S. Patent Office also issued to MiMedx U.S. Patent Number 8,709,493 and U.S. Patent Number 8,709,494, both also entitled “Placental Tissue Grafts.” Among other things, the four new patents further protect MiMedx’s layered allografts, including AmnioFix® and EpiFix® brand allografts.

“We are pleased to have been granted these four new patents, which now bring our total to 15 patents issued to MiMedx related to our allografts derived from the amniotic membrane,” said Parker H. “Pete” Petit, Chairman and CEO. “Human amnion/chorion tissue is rich in cytokines and growth factors known to promote wound healing. Our patented constructs cover multi-layered allografts and processes for making them. These layered allografts are designed to effectively provide cytokines and growth factors to the treatment site. We have developed a robust scientific foundation surrounding our allografts, and it is vital that we protect it. To do so, we have been very prolific in the filing of patent applications. In addition to our 15 issued patents, we have 49 pending patent applications related to our amnion/chorion technology that have been filed with the U.S. Patent and Trademark Office.”

Bill Taylor, President and COO, stated, “We have taken years and spent millions in Research & Development expenditures to complete the proprietary designs, methods and processes that preserve the critical properties of our allografts. The healing properties and other anti-inflammatory, barrier and scar formation reduction properties contained in our allografts enhance their leadership status in the market. Our science and technology will continue to reinforce MiMedx’ leadership position in the production of regenerative therapies and biomaterials produced from human amniotic membrane. We are committed to continuing our aggressive focus on Research & Development and the continual protection of the intellectual property that we have created.”

The Company also announced that it has amended its patent infringement lawsuit recently filed in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. (“Liventa”), Medline Industries, Inc. (“Medline”) and Musculoskeletal Transplant Foundation, Inc. (“MTF”), to add additional counts of infringement of MiMedx’s patents. In the amendment, MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringe two of these newly issued MiMedx patents:

1. US 8,703,207 – Placental Tissue Grafts.
2. US 8,709,494 – Placental Tissue Grafts.

Petit commented, “As we previously stated, we have responsibilities to prescribing physicians and their patients, as well as to our shareholders and employees to protect our intellectual property. This amendment to our previously filed lawsuit furthers our commitment to these responsibilities.”

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, express or implied statements about the Company’s ability to maintain and enforce patent and other intellectual property protection for its product portfolio. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the uncertainties of litigation, that the Company may be not able to protect the intellectual property of its product portfolio, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

Tuesday, April 29th, 2014 Uncategorized Comments Off on (MDXG) Issued Four New U.S. Patents For Placental Tissue Allografts

(CRTO) Platform Agnostic Complete Personalized Mobile Advertising Solution

-New capability critically important for advertisers seeing explosion in mobile sales via tablets -Criteo now generating over $1B in post-click mobile sales for customers on an annual run-rate -Criteo now delivers end-to-end performance advertising solution across online, mobile web and mobile apps for both iOS and Android platforms

PALO ALTO, Calif., April 29, 2014 /PRNewswire/ — Criteo (NASDAQ: CRTO), a leading global technology company that specializes in digital performance advertising, today announced the global availability of a complete mobile advertising solution. As consumers continue to transition to tablets and smartphones like the iPad and iPhone, Criteo helps marketers deliver more sales through personalized mobile ads in both browsers and apps. As part of this unique solution, Criteo works closely with clients to deliver a transparent, cookie-based solution that allows advertisers to serve personalized dynamic ads on Safari mobile web browsers, while empowering users to make a relevant choice regarding their browsing experience.

“Travelzoo’s strategic direction as a business is to act and think ‘mobile first’ – this step change over the past two years has contributed to an increase of more than 100% in mobile traffic to our deals.  Overall more than 40% of all traffic now comes from mobile devices and over half of this traffic is from the iOS platform.  As the Travelzoo business continues to innovate and improve its mobile offering we are committed to working with partners such as Criteo who understand the challenges and enormous opportunities inherent in mobile.  Working with Criteo enables us to effectively target and engage with our audience in the mobile space,” said Joel Brandon-Bravo, managing director at Travelzoo in the UK.

According to IBM’s Black Friday Report 2013, sales on mobile devices continue to skyrocket.  The study reported that 21.8 percent of all online sales came through a mobile device, which represents a year-over-year increase of 43 percent.  The spike in tablet adoption is a key contributor to the growth in mobile sales and tablet shipments are now exceeding those of desktops or laptops. As a result, it’s critically important for marketers to effectively reach and engage this growing mobile audience through mobile web browsers and in-app advertising.

Criteo introduced its in-app advertising solution in January and has seen rapid month-over-month growth.  The product is now live and gaining traction in the United States, the United Kingdom, France, Germany, Brazil and elsewhere. The momentum of Criteo’s in-app solution combined with its strong and growing traction in mobile web proves that mobile advertising is driving significant sales results.  In fact, Criteo is now generating over $1 billion in post-click mobile sales for its customers on an annual run-rate.

Driving a Consistent & Transparent User Experience, Regardless of Browser
Criteo’s complete mobile solution ensures that users receive personalized, relevant ads regardless of the web browser.  The company is a pioneer in providing consumer transparency over ad choices and helps users manage this by placing an interactive icon on all Criteo ads. Its technology uses information based on previous browsing behavior such as product viewed. With its innovative Safari solution, Criteo took a similar user-friendly approach.  When a user browses a client’s website with Safari and doesn’t have a Criteo cookie, Criteo will display an informative banner that notifies the user that their browser blocks some third-party cookies by default and that subsequently clicking on the website will allow Criteo to place its cookies and serve personalize ads.  After having accepted Criteo cookies by clicking on the website, the user is shown a second notice that offers them the ability to revert their choice in the event that they change their mind.

“Web Browser settings that prevent some third-party cookies by default make the delivery of relevant and customized advertising more difficult,” said Mike Zaneis, Executive Vice President, Public Policy & General Counsel, IAB.  “The IAB believes advertising companies delivering solutions that empower users to make informed decisions about their browsing experience and enable relevant customized ads are a benefit to the entire industry. One effective way to approach this question is by proactively displaying information to website visitors about the type of cookies used, how they are delivered and the options for managing. These innovative initiatives are also a great example of the self-regulatory programs favored by the Obama administration.”

“Our customers have been asking for a comprehensive solution for mobile advertising, so we’re delighted to announce the release of support for all browsers. Criteo has worked hard to deliver a unique solution that enables a privacy-centric cookie-based solution for Safari – the default mobile web browser for the most popular tablet and smartphone. This builds on our existing mobile browser technologies and is a powerful complement to our in-app and online offerings,” said Jonathan Wolf, Chief Product Officer at Criteo.  “With the introduction of new advertising capabilities, it’s also important for us to reaffirm Criteo’s commitment to upholding the highest levels of consumer privacy.  Privacy considerations are at the very center of everything we do, and we aim to deliver fantastic results for our clients, while ensuring consumers have privacy, transparency and control.”

For more information regarding Criteo’s mobile capabilities, recommendation and prediction engine and its digital performance advertising solutions, please visit www.criteo.com.

About Criteo
Criteo is a global leader in digital performance advertising, working with over 5,000 companies around the world. Criteo has over 800 employees in offices across the U.S., Europe and Asia serving more than 40 countries.
For more information, please visit http://www.criteo.com.

About Travelzoo
Travelzoo Inc. is a global Internet media company. With more than 26 million subscribers in North America, Europe, and Asia Pacific and 25 offices worldwide, Travelzoo® publishes deals from more than 2,000 travel, entertainment and local companies. Travelzoo Deal Experts review offers to find the best deals and confirm their true value. In Asia Pacific, Travelzoo is independently owned and operated by Travelzoo (Asia) Ltd. and Travelzoo Japan K.K. under a license agreement with Travelzoo Inc.

Tuesday, April 29th, 2014 Uncategorized Comments Off on (CRTO) Platform Agnostic Complete Personalized Mobile Advertising Solution

(LKQ) Announces Results of Exchange Offer of Senior Notes

CHICAGO, April 29, 2014  — LKQ Corporation (Nasdaq:LKQ) today announced the results of its offer to exchange (the “Exchange Offer”) up to $600,000,000 aggregate principal amount of its outstanding new registered 4.75% Senior Notes due 2023 (the “Exchange Notes”) for a like principal amount of its outstanding unregistered 4.75% Senior Notes due 2023. The CUSIP number for the Exchange Notes is 501889AB5.

According to information provided by the exchange agent, U.S. Bank National Association, $600,000,000 aggregate principal amount, or 100%, of the outstanding unregistered 4.75% Senior Notes due 2023 were tendered for exchange in the Exchange Offer. The Exchange Offer expired at 5:00 p.m., New York City time, on April 25, 2014.

This press release is for informational purposes only and is neither an offer to exchange, nor a solicitation of an offer to sell, the Exchange Notes. The Exchange Offer was made solely pursuant to the prospectus dated March 28, 2014, including any supplements thereto. The Exchange Offer was not made to holders in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky, or other laws of such jurisdiction.

About LKQ Corporation

LKQ Corporation (www.lkqcorp.com) is a leading provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. LKQ has operations in North America, the United Kingdom, the Netherlands, Belgium, France and Taiwan. LKQ operates more than 630 facilities, offering its customers a broad range of replacement systems, components, equipment and parts to repair and accessorize automobiles, trucks, and recreational and performance vehicles.

Forward Looking Statements

Certain statements in this press release that are not historical facts are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements generally include expectations, beliefs, hopes, intentions or strategies regarding our future, including with respect to the proposed transaction described and statements or assumptions regarding the expected timetable for completing the transaction and other statements that are based on management’s current beliefs and expectations of the company. Forward looking statements are subject to risks, uncertainties and other factors some of which are not currently known to us. Actual events or results may differ materially from those expressed or implied in the forward looking statements as a result of various factors. Some of such risks, uncertainties and other factors are described in our Form 10-K for the period ended December 31, 2013 filed on March 3, 2014 and in other reports filed by us from time to time with the Securities and Exchange Commission. We assume no obligation to publicly update any forward looking statement to reflect events or circumstances arising after the date on which it was made, except as required by law.

CONTACT: Joseph P. Boutross-LKQ Corporation
         Director, Investor Relations
         (312) 621-2793
         jpboutross@lkqcorp.com
Tuesday, April 29th, 2014 Uncategorized Comments Off on (LKQ) Announces Results of Exchange Offer of Senior Notes

(SHIP) Signs Strategic Agreement for the Contribution of Four Capesize Vessels

ATHENS, GREECE–(Apr 29, 2014) – Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that the Company has entered into an agreement with entities affiliated with certain members of the Restis family (the “Sellers” or “Major Shareholders”) for the contribution of four Capesize vessels as equity, in exchange for newly issued shares of the Company’s common stock.

Pursuant to the agreement, certain of the Company’s Major Shareholders will contribute to the Company four Capesize vessels with a current market value appraised at approximately $178 million and estimated net asset value of approximately $86 million.

The transaction remains subject to certain closing conditions, including Sellers’ lenders’ approval and other standard legal documentation and is expected to be completed by June 30, 2014. The Company’s Board of Directors will obtain a fairness opinion from a reputable financial firm for this transaction.

Following the completion of the transaction, the Company will have a modern fleet of four Capesize dry bulk carriers with a combined cargo-carrying capacity of approximately 682,723 dwt and an average fleet age of about 7.5 years. Upon delivery, the vessels are expected to be employed in the spot market or under index-linked charter agreements and consequently the Company will start earning revenue immediately upon completion of the transaction. As a result, indicatively, based on current consensus estimates by research analysts for 2014 and 2015 charter rates, these vessels are expected to generate aggregate revenues of approximately $36 million and aggregate EBITDA of approximately $25 million during the 12-month period following the closing of the transaction. The Company will evaluate future employment options based on prevailing spot and period rates.

As of March 31, 2014, the Company’s shareholders’ equity was approximately $2.6 million. The exact amount of the increase in the Company’s shareholders’ equity as a result of this transaction will be determined on the closing date of the transaction.

Stamatis Tsantanis, the Company’s Chairman and Chief Executive Officer, stated: “This transaction represents a new era for Seanergy as we rebuild our fleet starting with four modern Capesize vessels that will immediately generate cash flows. Moreover, this contribution represents a strong vote of confidence in our business plan, which we have successfully implemented so far. Our objective is to grow the Company through accretive transactions and deliver substantial shareholder returns for the long term.”

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is a Marshall Islands corporation with its executive offices in Athens, Greece. The Company is engaged in the transportation of dry bulk cargoes through the ownership and operation of dry bulk carriers.

Currently, the Company does not own any operating vessels. Following the closing of the transaction announced with this press release, the Company’s fleet will be consisted of 4 Capesize dry bulk carriers with a combined cargo-carrying capacity of approximately 682,723 dwt and an average fleet age of 7.5 years.

The Company’s common stock trades on the NASDAQ Capital Market under the symbol “SHIP”.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that such expectations will prove to have been correct, these statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the scope and timing of Securities and Exchange Commission (“SEC”) and other regulatory agency review, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the SEC. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Investor Relations / Media
Capital Link, Inc.
Paul Lampoutis
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: seanergy@capitallink.com

Tuesday, April 29th, 2014 Uncategorized Comments Off on (SHIP) Signs Strategic Agreement for the Contribution of Four Capesize Vessels

(MNGA) Distributor Sidney Lee Welding Receives First Customer Order

Large Georgia Machine Shop Impressed by 50% Increased Cutting Speed

TAMPA, Fla., April 29, 2014  — MagneGas Corporation, www.magnegas.com (“MagneGas” or the “Company”) (NASDAQ: MNGA), a technology company that counts among its inventions a patented process that converts liquid waste into a hydrogen-based fuel, announced today that Sidney Lee Welding Inc. of Georgia has completed MagneGas Distributor training and has received their first customer order. Sidney Lee recently purchased $10,000 of MagneGas® fuel, which amounted to approximately an entire semi-truck of cylinders.  After receiving their order, MagneGas personnel conducted extensive training with the Sidney Lee team who have now started actively selling MagneGas® fuel in the Georgia market.

A large local machine shop was the first customer to place an order after using MagneGas® for cutting a four inch plate on their computerized cutting table.  They found improved cutting speeds of 13.5 inches per minute with MagneGas® versus 9 inches per minute with propylene, a 50% improvement. The improved cutting speeds coupled with almost no pre-heating time and visibly cleaner cut resulted in MagneGas getting the order.

“We are very pleased to be working with Sidney Lee Welding in Georgia.  Their first customer, which is a very large local machine shop, is exactly the kind of organization which we are targeting for the MagneGas® metal cutting gas,” stated Terry Vernille, Executive Vice-President of Industrial Gas Sales for MagneGas.

The MagneGas IR App is now available for free in Apple’s App Store for the iPhone or iPad http://bit.ly/AfLYww and at Google Play http://bit.ly/Km2iyk for Android mobile devices.

To be added to the MagneGas investor email list, please email pcarlson@kcsa.com with MNGA in the subject line.

About MagneGas Corporation
Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is a technology Company that counts among its inventions, a patented process that converts liquid waste into hydrogen based fuels.  The Company currently sells MagneGas® into the metal working market as a replacement to acetylene.  It is also selling equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets.  In addition, the Company is developing a variety of ancillary uses for MagneGas® fuels utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications.  For more information on MagneGas®, please visit the Company’s website at www.MagneGas.com.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using new ethylene glycol to produce fuel until proper permits to process used liquid waste have been obtained.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

Tuesday, April 29th, 2014 Uncategorized Comments Off on (MNGA) Distributor Sidney Lee Welding Receives First Customer Order

(FOLD) Announces Positive 12- and 24-Month Monotherapy Study Data

Migalastat Demonstrated Statistically Significant (p=0.013) and Durable Substrate Reductions on 12-Month Pre-Specified Primary Analysis in Fabry Patients with Amenable Mutations

Statistically Significant (p<0.0001) Reduction Also Seen in Important Fabry Disease Biomarker, Plasma Lyso-Gb3

Kidney Function Remained Stable Up to 24 Months in Fabry Patients with Amenable Mutations

85% of Patients with Amenable Mutations Completing Month 24Remain in Ongoing Voluntary Extension Study (Study 041)

Conference Call and Webcast Today at 8:00 a.m. ET

CRANBURY, N.J., April 29, 2014  — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced positive 12- and 24-month data from its first Phase 3 study (Study 011) of the oral small molecule chaperone migalastat HCl (“migalastat”) monotherapy in Fabry patients with amenable mutations. Detailed results are available in a slide presentation that will be shared by the Amicus management team on a conference call today at 8:00 a.m. ET. Please visit http://ir.amicustherapeutics.com/events.cfm.

Study 011 was designed to measure the reduction of disease substrate (Globotriaosylceramide, or GL-3) following treatment with migalastat. The 24-month study began with a 6-month double-blind, placebo-controlled treatment period, after which all patients were treated with migalastat for a 6-month open-label follow-up period and a subsequent 12-month open-label extension phase. The study also measured clinical outcomes, including renal function, as secondary endpoints.

As previously reported, patients on migalastat experienced greater reductions in GL-3 as compared to placebo during the initial 6-month period; however, this difference was not statistically significant under the original study primary endpoint (responder analysis with a 50% reduction threshold at month 6). Following a Type C Meeting with the U.S. Food and Drug Administration (FDA) in the second quarter of 2013, and based on feedback from the agency at that meeting, Amicus revised the Statistical Analysis Plan to pre-specify the primary analysis at month 12 as the mean change in GL-3 in patients with amenable mutations in a GLP-validated human embryonic kidney (HEK) cell-based in vitro assay (“GLP HEK amenable”).

Summary of Study 011 12- and 24-Month Data in GLP HEK Amenable Patients

  • Subjects who switched from placebo to migalastat after month 6 demonstrated a statistically significant reduction in kidney interstitial capillary GL-3 at month 12 (p=0.013).
  • Subjects who remained on migalastat for 12 months demonstrated a durable reduction in kidney interstitial capillary GL-3.
  • Reduction in disease substrate was also observed in plasma lyso-Gb3, another important biomarker of disease, in subjects who switched from placebo to migalastat (p<0.0001). Subjects who remained on migalastat demonstrated a durable reduction in lyso-Gb3.
  • Kidney function (estimated glomerular filtration rate (eGFR), iohexol mGFR) remained stable over 18-24 months
  • Migalastat was generally safe and well-tolerated.
  • Of 41 subjects with GLP HEK amenable mutations who completed Study 011, 35 (85%) remain in the voluntary extension study (Study 041).

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “Today is a great day for Amicus and the Fabry community. We are pleased to report that the 12 and 24 month results from Study 011 have met our pre-defined criteria for success in terms of substrate reduction at 12 months, as well as clinical measures of kidney function maintained out to 24 months. We believe these data provide important validation that a small-molecule chaperone can restore the function of a patient’s own enzyme in patients with amenable mutations, and that our pharmacogenomic assays can identify these patients. Together these results demonstrate the power of personalized medicine in rare diseases and offer the prospect of a new treatment option that differs from traditional enzyme replacement therapy. Pending positive data from our second Phase 3 study we expect to meet with regulatory authorities to discuss these data and determine the fastest registration pathway for migalastat.”

Raphael Schiffmann, M.D., M.H.Sc., Director of the Institute of Metabolic Disease, Baylor Research Institute, stated, “As an investigator experienced in treating patients with migalastat for up to 8 years in clinical studies, I believe the results from Study 011 show a positive treatment effect of migalastat in Fabry patients with amenable mutations. The reductions in substrate levels in the kidney and in plasma, combined with stabilization of renal function, strongly suggest that migalastat may become an important new oral treatment option for Fabry patients.”

Migalastat monotherapy is being investigated in two Phase 3 registration studies (Study 011 and Study 012) and an open-label extension study (Study 041) in Fabry patients with amenable mutations. Top-line data are anticipated in the third quarter of 2014 from Study 012. The primary analysis in Study 012 will evaluate GFR, a clinical measure of kidney function, over 18-months of treatment with migalastat compared to enzyme replacement therapy (ERT), the current standard of care for Fabry disease.

Robert Desnick, M.D., Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus, Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai stated, “Over 40 years of working with patients with Fabry disease, participating in the development of enzyme replacement therapy, and as an early advocate of chaperone therapy, I believe there remains an unmet medical need among these patients. Study 011 has generated an impressive data set demonstrating that patients with amenable mutations respond to migalastat as a chaperone monotherapy.”

Study 011 Substrate Reduction Data in GLP HEK Amenable Patients

Migalastat has demonstrated significant and durable reductions in GL-3 in Study 011 in patients with GLP HEK amenable mutations. Reductions in plasma Lyso-Gb3, another important disease biomarker, were also observed in patients with GLP HEK amenable mutations. GL-3 is the substrate that accumulates in patients with Fabry disease. Reduction in kidney interstitial capillary GL-3 is a surrogate biomarker that was used to support U.S. approval of ERT for Fabry disease.

Study 011 Stage 1 Data
(Baseline to Month 6)
Study 011 Stage 2 Data
(Month 6 to Month 12)
  Migalastat Group1 Placebo
Group2
p-Value Migalastat Group1 Placebo-
Migalastat
Crossover
Group2
p-Value
Mean Change in GL-3 (SEM) (Baseline Corrected)3 -0.25 ± 0.10
(n=25)
+0.07 ± 0.13 (n=20) 0.008** +0.01 ± 0.011
(n=22)
-0.31 ± 0.10 (n=17) 0.013*
Plasma Lyso-Gb3 (SEM) -11.2 ± 4.8
(n=18)
+0.6 ± 2.4
(n=13)
0.0033** +1.2 ± 1.3
(n=18)
-15.5 ± 6.2
(n=13)
<0.0001**

Study 011 Kidney Function Data in GLP HEK Amenable Patients

Among patients with GLP HEK amenable mutations in Study 011, kidney function by various measures of glomerular filtration rate (GFR) has remained stable for up to 24 months following treatment with migalastat. Decline in kidney function is a key cause of mortality in patients with Fabry disease.

  Mean Annualized Change in GFR (ml/min/m2/yr) (SEM)
Over 18 to 24 Months (Preliminary Data)
Estimated GFR (eGFR) (CKD-EPI) (n=41) -0.30 (0.66)
eGFR (MDRD) (n=41) +0.79 (1.03)
Iohexol (Measured) GFR (n=37) -1.51 (1.33)

About Study 011 Statistical Analyses

The primary endpoint in Study 011 analyzed the percent change in kidney interstitial capillary GL-3 inclusions from baseline to month 6 (responder analysis with a 50% reduction threshold). As previously reported, the variability and low levels of GL-3 at baseline contributed to a higher-than-anticipated placebo response at month 6. Following the unblinding of the 6-month data, and while still blinded to the 12-month data, Amicus identified the mean change in GL-3 as a more appropriate way to control for the variability in GL-3 levels in Study 011 and to measure the biological effect of migalastat.

Amicus analyzed and previously reported the mean change in GL-3 from baseline to month 6 as a post-hoc analysis, including a subgroup analysis in patients with GLP HEK amenable mutations that further supports use of the GLP HEK assay in predicting responsiveness to migalastat. Following a Type C Meeting with the U.S. Food and Drug Administration, Amicus revised the Statistical Analysis Plan to pre-specify the primary analysis at month 12 as the mean change in GL-3 in patients with GLP HEK amenable mutations.

About GLP HEK Amenable Mutations

Amenable mutations are defined as having an absolute increase of 3% of wild type alpha-Gal A enzyme activity and a relative increase of 20% when exposed to migalastat in a cell-based in vitro assay. All subjects enrolled in Study 011 had amenable mutations in the clinical trial human embryonic kidney (HEK) assay available at study initiation (“clinical trial assay”). Following the completion of enrollment, a GLP HEK assay was developed with a third party to measure the criteria for amenability with more quality control and rigor. However, approximately 10% of mutations in the HEK database switched categorization between “amenable” and “non-amenable” when moving from the clinical trial assay to the GLP HEK assay. Therefore there were changes in categorization from amenable to non-amenable in 17 patients in Study 011.

Overall based on results from mutations tested in the GLP HEK assay, Amicus continues to believe that approximately 30% to 50% of the Fabry population have mutations that are amenable to migalastat.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, April 29, 2014 at 8:00 a.m. ET to discuss positive 12- and 24-month results from Study 011. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). The slide presentation for the conference call is available at http://ir.amicustherapeutics.com/events.cfm.

An audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 11:00 a.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 37179299.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

1Patients with GLP HEK amenable mutations who received migalastat from baseline to month 24

2Patients with GLP HEK amenable mutations who received placebo from baseline to month 6 and switched to migalastat after month 6

3Mean change in number of inclusions per capillary as a continuous variable (assessed by histology in kidney biopsies). Scores averaged across all reads at baseline, month 6 and month12.

*MMRM analyzing change in placebo group from month 6 to month 12

**ANCOVA model with covariate adjustment for baseline value and treatment-by-baseline interaction

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products and the projected cash position for the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044

         Media:
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085
Tuesday, April 29th, 2014 Uncategorized Comments Off on (FOLD) Announces Positive 12- and 24-Month Monotherapy Study Data

(CHTR) and Comcast Reach Agreement on Divestitures

Comcast to Divest 3.9 Million Customers of Merged Comcast – Time Warner Cable Charter to Enhance Scale and Improve Geographic Footprint Divestiture will be Executed through Three Separate Transactions, Including the Creation of a New, Independent, Publicly-Traded Cable Provider

PHILADELPHIA and STAMFORD, Conn., April 28, 2014  — Comcast Corporation (Nasdaq: CMCSA, CMCSK) and Charter Communications (Nasdaq: CHTR) today announced that the companies have reached an agreement (the “Agreement”) on a series of tax-efficient transactions, whereby the combined Comcast-Time Warner Cable entity, following completion of Comcast’s previously announced merger with Time Warner Cable, will divest systems resulting in a net reduction of approximately 3.9 million video customers. The divestiture follows through on Comcast’s willingness to reduce its post-merger managed subscriber total to less than 30 percent of total national MVPD subscribers, while maintaining the compelling strategic and financial rationale of its proposed merger with Time Warner Cable.

Pursuant to the Agreement, and following the close of the Comcast-Time Warner Cable merger, Charter will acquire approximately 1.4 million existing Time Warner Cable subscribers, increasing Charter’s current residential and commercial video customer base from 4.4 million to approximately 5.7 million, and making Charter the second largest cable operator in the United States.[1]  Charter and Comcast will also each transfer approximately 1.6 million customers respectively. In addition, Charter, through a tax free reorganization, will form a new holding company (New Charter) that will own 100% of Charter, and acquire an approximate 33 percent stake in a new publicly-traded cable provider to be spun-off by Comcast serving approximately 2.5 million customers (“SpinCo”). Charter will provide management services to SpinCo. In aggregate, today’s announced transactions will significantly enhance Charter’s scale and improve both companies geographic footprint, driving operational efficiencies for Comcast, Charter and SpinCo.

The Agreement has been approved by the Boards of Directors of both companies and Time Warner Cable’s Board has consented to the Agreement as required under the Comcast-Time Warner Cable merger agreement.

The Agreement will be executed via three separate transactions, which are subject to the completion of the proposed Comcast-Time Warner Cable merger:

  1. Comcast will divest Time Warner Cable systems serving approximately 1.4 million existing Time Warner Cable customers directly to Charter for cash. Charter expects to fund the purchase with proceeds from debt, and to have approximately a 5 times debt to EBITDA leverage ratio at closing.
  2. Comcast and Charter will transfer assets serving approximately 1.6 million existing Time Warner Cable customers and 1.6 million Charter customers in a tax-efficient like kind exchange, improving the geographic presence of both companies, leading to greater operational efficiencies, improved technology deployment and enhanced customer service.
  3. Comcast will form and spin off to its shareholders a new, independent, publicly-traded company that will operate systems serving approximately 2.5 million existing Comcast customers. Comcast shareholders, including the former Time Warner Cable shareholders, are expected to own approximately 67 percent of SpinCo, while New Charter is expected to directly own approximately 33 percent of SpinCo. SpinCo expects to incur leverage of approximately 5 times estimated pro-forma EBITDA, and New Charter will then acquire its interest in SpinCo by issuing New Charter stock to Comcast shareholders (including former Time Warner Cable shareholders). SpinCo’s nine-member Board of Directors will include six independent directors and three directors designated by Charter. Comcast will hold no ownership interest in SpinCo (or Charter) and will have no role in managing SpinCo.

The transfer of systems, asset purchase and SpinCo acquisition will be valued at a 7.125 times 2014 EBITDA multiple (as defined by the parties), and Charter will make additional payments to Comcast over time as tax benefits from the asset sale are realized.

As a result of these transactions, following the completion of the merger between Comcast and Time Warner Cable, Comcast’s managed residential subscribers will be below 30 percent of the total MVPD subscribers in the United States, and approximately the same market share as Comcast’s subscriber base after its completion of both the 2002 AT&T Broadband transaction and the 2006 Adelphia transaction – and Charter’s subscriber base will increase by 1.4 million to a total of 5.7 million.

Comcast has reaffirmed that, after taking into account the transactions with Charter, it continues to expect its merger with Time Warner Cable to generate approximately $1.5 billion in operating efficiencies. Comcast shareholders will receive meaningful value with shares in New Charter, as well as new shares in SpinCo. In addition, Comcast intends to use proceeds from these transactions to reduce its debt in a leverage-neutral manner and expand its share buyback program.

“Today’s Agreement follows through on our willingness to divest subscribers, while also marking an important step in our merger with Time Warner Cable,” said Brian Roberts, Chairman and Chief Executive Officer, Comcast Corporation. “These transactions enable us to deliver meaningful value to our shareholders. The realignment of key cable markets achieved in these transactions will enable Comcast to fill in our footprint and deliver operational efficiencies and technology improvements. We look forward to working with the management teams at Time Warner Cable, Charter and the new entity to close these transactions and ensure a smooth transition for the customers and employees of all companies.”

“Charter’s new customers will benefit from our philosophy of providing highly valued products, featuring enhanced on-demand, interactive video and increased broadband speeds, all in a simplified package designed to provide better value and service,” said Tom Rutledge, President and Chief Executive Officer of Charter Communications. “The transactions announced today will provide Charter with greater scale, growth opportunities and improved geographical rationalization of our cable systems, which in turn will drive value for shareholders and more effective customer service. And through our meaningful ownership in and board representation at SpinCo, we can help it achieve similar market share growth in the markets it serves.”

The transactions are subject to a number of conditions, including the closing of the Comcast-Time Warner Cable merger, receipt of Hart-Scott-Rodino, FCC and other required regulatory approvals, Charter shareholder approval, and various other matters.

J.P. Morgan and Paul J. Taubman acted as financial advisors to Comcast and Davis Polk & Wardwell LLP and Willkie Farr & Gallagher LLP are its legal advisors.

Goldman Sachs and LionTree Advisors are serving as lead financial advisors to Charter in connection with this transaction. Guggenheim Securities is also a financial advisor to Charter. BofA Merrill Lynch, Credit Suisse, and Deutsche Bank Securities Inc. are also financial advisors to Charter, and together with Goldman Sachs, are leading the financing for the transaction. The law firms Wachtell, Lipton, Rosen & Katz and Kirkland & Ellis LLP are also representing Charter.

Teleconference and Webcast for Financial Community
Charter and Comcast will host a conference call on Monday, April 28, 2014 at 8:00 a.m. Eastern Time (ET) related to the contents of this release.

The conference call will be webcast live via Charter’s website at charter.com. The webcast can be accessed by selecting “Investor & News Center” from the lower menu on the home page. The call will be archived in the “Investor & News Center” in the “Financial Information” section on the left beginning two hours after completion of the call. Participants should go to the webcast link no later than 10 minutes prior to the start time to register.

The conference call and related materials will also be broadcast live and posted on Comcast’s Investor Relations website at www.cmcsa.com or www.cmcsk.com.

Those participating via telephone should dial 866-919-0894 no later than 10 minutes prior to the call. International participants should dial 706-679-9379. The conference ID code for the call is 35997372. A replay of the call will be available at 855-859-2056 or 404-537-3406 beginning two hours after the completion of the call through the end of business on May 28, 2014. The conference ID code for the replay is 35997372.

About Comcast Corporation
Comcast Corporation (Nasdaq: CMCSA, CMCSK) is a global media and technology company with two primary businesses, Comcast Cable and NBCUniversal. Comcast Cable is the nation’s largest video, high-speed Internet and phone provider to residential customers under the XFINITY brand and also provides these services to businesses. NBCUniversal operates 30 news, entertainment and sports cable networks, the NBC and Telemundo broadcast networks, television production operations, television station groups, Universal Pictures and Universal Parks and Resorts. Visit www.comcastcorporation.com for more information.  

About Charter Communications
Charter (NASDAQ: CHTR) is a leading broadband communications company and the fourth-largest cable operator in the United States. Charter provides a full range of advanced broadband services, including advanced Charter TV® video entertainment programming, Charter Internet® access, and Charter Phone®. Charter Business® similarly provides scalable, tailored, and cost-effective broadband communications solutions to business organizations, such as business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Charter’s advertising sales and production services are sold under the Charter Media® brand. More information about Charter can be found at charter.com.

Important Information For Investors And Shareholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.  In connection with the proposed transaction between Comcast Corporation (“Comcast”) and Charter Communications, Inc. (“Charter”), Charter will file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that will include a proxy statement of Charter that also constitutes a prospectus of Charter, and a definitive proxy statement/prospectus will be mailed to shareholders of Charter. INVESTORS AND SECURITY HOLDERS OF COMCAST AND CHARTER ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the proxy statement/prospectus (when available) and other documents filed with the SEC by Comcast or Charter through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by Comcast are available free of charge on Comcast’s website at http://cmcsa.com or by contacting Comcast’s Investor Relations Department at 866-281-2100. Copies of the documents filed with the SEC by Charter will be available free of charge on Charter’s website at charter.com, in the “Investor and News Center” near the bottom of the page, or by contacting Charter’s Investor Relations Department at 203-905-7955.

In addition, in connection with the proposed transaction between Comcast and Time Warner Cable Inc. (“Time Warner Cable”), on March 20, 2014, Comcast filed with the SEC a registration statement on Form S-4 containing a preliminary joint proxy statement of Comcast and Time Warner Cable that also constitutes a preliminary prospectus of Comcast.  The registration statement has not yet become effective.  After the registration statement is declared effective by the SEC, a definitive joint proxy statement/prospectus will be mailed to shareholders of Comcast and Time Warner Cable.  INVESTORS AND SECURITY HOLDERS OF COMCAST AND TIME WARNER CABLE ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.  Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by Comcast or Time Warner Cable through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by Comcast are available free of charge on Comcast’s website at http://cmcsa.com or by contacting Comcast’s Investor Relations Department at 866-281-2100.  Copies of the documents filed with the SEC by Time Warner Cable will be available free of charge on Time Warner Cable’s website at http://ir.timewarnercable.com or by contacting Time Warner Cable’s Investor Relations Department at 877-446-3689.

Shareholders of Comcast and Time Warner Cable are not being asked to vote on the proposed transaction between Comcast and Charter, and the proposed transaction between Comcast and Time Warner Cable is not contingent upon the proposed transaction between Comcast and Charter.

Comcast, Time Warner Cable, Charter and their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction between Comcast and Time Warner Cable, and Comcast, Charter and their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction between Comcast and Charter. Information about the directors and executive officers of Time Warner Cable is set forth in its Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 18, 2014, and its preliminary proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on April 8, 2014.  Information about the directors and executive officers of Comcast is set forth in its Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 12, 2014, and its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on April 11, 2014. Information about the directors and executive officers of Charter is set forth in its Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 21, 2014, and its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 27, 2014.  These documents can be obtained free of charge from the sources indicated above.  Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the preliminary joint proxy statement/prospectus of Comcast and Time Warner Cable filed with the SEC and will be contained in the definitive joint proxy statement/prospectus of Comcast and Time Warner Cable and other relevant materials to be filed with the SEC when they become available, and will also be contained in the preliminary proxy statement/prospectus of Charter when it becomes available.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this communication regarding the proposed acquisition of Time Warner Cable by Comcast and the proposed transaction between Comcast and Charter, including any statements regarding the expected timetable for completing the transactions, benefits and synergies of the transactions, future opportunities for the respective companies and products, and any other statements regarding Comcast’s, Time Warner Cable’s and Charter’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements are often, but not always, made through the use of words or phrases such as “may”, “believe,” “anticipate,” “could”, “should,” “intend,” “plan,” “will,” “expect(s),” “estimate(s),” “project(s),” “forecast(s)”, “positioned,” “strategy,” “outlook” and similar expressions. All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are the following: the timing to consummate the proposed transactions; the risk that a condition to closing either of the proposed transactions may not be satisfied; the risk that a regulatory approval that may be required for either of the proposed transactions is not obtained or is obtained subject to conditions that are not anticipated; the parties’ ability to achieve the synergies and value creation contemplated by the proposed transactions; the parties’ ability to promptly, efficiently and effectively integrate acquired operations into their own operations; and the diversion of management time on transaction-related issues. Additional information concerning these and other factors can be found in Comcast’s, Time Warner Cable’s and Charter’s respective filings with the SEC, including Comcast’s, Time Warner Cable’s and Charter’s most recent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  Comcast, Time Warner Cable and Charter assume no obligation to update any forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

[1]Charter customer count is based on its reporting methodologies; net additions and SpinCo on respective TWC and Comcast reporting methodologies, where there may be small definitional differences.  Totals may not recalculate due to rounding.

Monday, April 28th, 2014 Uncategorized Comments Off on (CHTR) and Comcast Reach Agreement on Divestitures

(NEPT) Acasti and NeuroBioPharm Announce Resignation of CEO

LAVAL, Quebec, April 28, 2014  — Neptune Technologies & Bioressources Inc. (“Neptune“) (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. (“Acasti“) (Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. (“NeuroBio“) today jointly announce the resignation of Henri Harland as President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect. Mr. Harland remains a Director of Neptune, Acasti and NeuroBio.

“I would like to thank Henri for his significant contributions as founder and executive of Neptune and its subsidiaries and wish him success in the future,” said Dr. Ronald Denis, Chairman of Neptune.

The businesses will continue to be managed by a management and operations committee under the leadership of Neptune’s Chief Financial Officer, Mr. André Godin. The search for a new President and Chief Executive Officer will commence immediately.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (“PUFAs“). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune respectively holds approximately 49% of the participating and voting rights of Acasti and 96% of the voting rights of NeuroBio. Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre®, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

About Acasti Pharma Inc.

Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and PUFAs, mainly eicosapentaenoic acid (“EPA“) and docosahexaenoic acid (“DHA“), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre®, currently Acasti’s only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA®, a medical food and currently Acasti’s only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre®.

About NeuroBioPharm Inc.

NeuroBio is an emerging biopharmaceutical company focused on the research, development and commercialization of new marine based omega‐3 phospholipid therapies for use in the human neurological field, including conditions, abnormalities and/or diseases related to cognitive functions such as attention, memory, concentration and learning and the management of neurological and neurodevelopmental disorders from prevention to treatment. NeuroBio is currently in the early stages of developing novel active pharmaceutical ingredients into commercial products for the medical food, the over‐the‐counter and the prescription drug markets. Particular focus is being given to attention-deficit hyperactivity disorder, cognitive functions, including memory and concentration, along with mood disorders, such as anxiety and depression.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune, Acasti and NeuroBio to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune, Acasti and NeuroBio’s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Except as required by law, Neptune, Acasti and NeuroBio disclaim any intention or obligation to update or revise any forward-looking statements.

“Neither NASDAQ, the Toronto Stock Exchange nor the TSX Venture Exchange accepts responsibility for the adequacy or accuracy of this release.”

CONTACT: Neptune, Acasti and NeuroBio Contacts:         
         Andre Godin
         Chief Financial Officer, Neptune
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com

         John Ripplinger
         Investor Relations
         +1.450.687.2262
         j.ripplinger@neptunebiotech.com
         www.neptunebiotech.com
Monday, April 28th, 2014 Uncategorized Comments Off on (NEPT) Acasti and NeuroBioPharm Announce Resignation of CEO

(RNA) to Present at the 66th Annual American Academy of Neurology

Leiden, The Netherlands, April 28, 2014  — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that it will present at the following US conferences:

66th American Academy of Neurology (AAN) Annual Meeting, Philadelphia, PA

Poster presentation: Emerging Science Session: 6:15pm EDT on Wednesday, April 30, 2014

Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials

Presenter: Dr. Nathalie Goemans

The poster includes results up to Week 48 from the second open-label extension study of drisapersen treatment in boys with DMD (DEMAND IV/DMD114349), who had previously completed a 48-week, double-blind, placebo-controlled treatment phase in one of two Phase II feeder studies (DEMAND II/DMD114117 and DEMAND III/DMD114044).

Breakfast Briefing (by invitation only): 7:30 -9:00am EDT on Thursday, May 1, 2014

Corporate Update: Hans Schikan, CEO & Giles Campion, CMO

Poster Presentation: Dr. Nathalie Goemans

Q&A: Prosensa Management, Dr. Nathalie Goemans (live) and Dr. Craig McDonald (by phone)

Dr. Goemans is a pediatrician, child neurologist and Head of the Neuromuscular Reference Center for Children at the University Hospitals Leuven (UHL). She is actively involved in the development of protocols for international multicentre trials and is an investigator in clinical trials in Duchenne Muscular Dystrophy (DMD).

Dr. McDonald is a Professor and Chair of Physical Medicine and Rehabilitation and a Professor of Pediatrics at the University of California Davis School of Medicine. He is an internationally recognized expert in the clinical management and rehabilitation of neuromuscular diseases including muscular dystrophies and the development of novel outcome measures for clinical trials.

39th Annual Deutsche Bank Health Care Conference, Boston, MA

Fireside Chat: 2:10pm EDT on Wednesday, May 7, 2014; Berndt Modig, CFO

Live webcasts of Prosensa’s presentations at the AAN Breakfast Briefing and the Deutsche Bank Health Care Conference will be accessible through the Investors & Media section of the corporate website at http://ir.prosensa.eu/events.cfm and will be archived for 90 days.

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington’s disease.

Prosensa’s current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com

CONTACT: Prosensa Holding N.V.
         Celia Economides, Senior Director IR & Corporate Communications
         Phone: +1 917 941 9059
         Email: c.economides@prosensa.nl
Monday, April 28th, 2014 Uncategorized Comments Off on (RNA) to Present at the 66th Annual American Academy of Neurology

(AGEN) Antibody-Based Cancer Immunotherapies Collaboration, License Agreement with Merck

Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display® platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.

Under the terms of the agreement, Agenus is eligible to receive approximately $100 million in potential payments associated with the completion of certain clinical, regulatory and commercial milestones for two candidates from Merck. In addition, Agenus is eligible to receive royalty payments on worldwide product sales.

“We are delighted to be working with Merck, who is a leader in the rapidly developing immuno-oncology space,” said Bob Stein, MD, PhD, Chief Scientific Officer of Agenus Inc. “We believe our Retrocyte Display technology has significant advantages for creation of high quality antibody development candidates. This collaboration broadens our efforts in immuno-oncology beyond our previously disclosed checkpoint programs with a world-class research and development partner.”

“This collaboration with Agenus complements our active immuno-oncology discovery programs,” said Dr. Eric Rubin, vice president clinical oncology, Merck Research Laboratories. “We look forward to working to advance these programs with the potential to address the unmet medical needs of people with cancer.”

Agenus acquired 4-Antibody AG, a private European-based biopharmaceutical company in February 2014. The 4-Antibody assets include the Retrocyte Display technology platform for discovery and optimization of fully human antibodies against a wide array of molecular targets. Agenus has multiple preclinical checkpoint modulator programs in development including GITR and OX40 agonists and antagonists of TIM-3, LAG-3, PD-1 and CTLA-4. These programs are being pursued through a strategic collaboration with Ludwig Cancer Research.

About Checkpoint Modulators

Clinical data from studies employing monoclonal antibodies that bind to checkpoint molecules, such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have generated considerable excitement in the field of immuno-oncology. Checkpoints are employed by the body to prevent a runaway immune response, which can be debilitating or deadly. Unfortunately, these very same checkpoint mechanisms can also be used by cancer cells as a defense against immune attack. Antibodies that bind to PD-1 and CTLA-4 are designed to help immune cells overcome the checkpoint defenses of cancer cells. Other checkpoint proteins, such as GITR and OX40, are receptors found on T cells that stimulate immune function. Agenus and Ludwig Cancer Research are driving leading-edge programs to discover and develop fully human monoclonal antibodies that bind to key checkpoint proteins and activate or block their activities for use in cancer therapy.

About Agenus

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® is used to generate fully human therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 22 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

Retrocyte Display and QS-21 Stimulon are registered trademarks of Agenus and its subsidiaries.

Monday, April 28th, 2014 Uncategorized Comments Off on (AGEN) Antibody-Based Cancer Immunotherapies Collaboration, License Agreement with Merck

(FURX) Forest Laboratories Acquisition For $1.1 Billion in Cash To Solidify Lead In Gastroenterology

Forest Laboratories, Inc. (NYSE:FRX) and Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval. The acquisition is subject to receipt of customary regulatory approvals and approval by Furiex shareholders.

Forest concurrently announced that it has entered into an agreement with Royalty Pharma to sell Furiex’s royalties on alogliptin and Priligy® to Royalty Pharma for approximately $415 million upon successful completion of Forest’s acquisition of Furiex. Forest’s acquisition of Furiex is not contingent on Forest’s agreement with Royalty Pharma.

“The acquisition of Furiex builds on our growing position in gastroenterology and helps to create a leading GI company within Forest. It is a natural extension of our GI business following our $2.9 billion acquisition of Aptalis earlier this year,” said Brent Saunders, Chief Executive Officer and President of Forest Laboratories, Inc. “We believe eluxadoline will be very complementary to our anchor GI product Linzess and additive to our broader GI portfolio, making us more relevant to gastroenterologists and primary care physicians. With eluxadoline, we expect to have one of the broadest product offerings for the $38 billion GI disease market.”

Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist and a delta opioid receptor antagonist for treating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-d). IBS-d affects approximately 28 million patients in the United States and Europe. In February, Furiex announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of IBS-d met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain. Furiex is on track to submit a New Drug Application for eluxadoline by the end of the third quarter of 2014.

“Furiex has built a strong portfolio of life-improving therapies for patients, including development stage assets and royalty-bearing products. Forest’s acquisition of our company is a testament to the strength of the business we have built,” said Fred Eshelman, founding chairman of Furiex. “I am very proud of our team for its hard work and excellent development of eluxadoline in just under four years. There is a strong business fit between Furiex and Forest, and eluxadoline is expected to contribute to Forest’s leading GI franchise.”

The terms of the merger agreement provide for Forest to pay $95 per share to Furiex shareholders. In addition, Forest agreed to make additional payments to Furiex shareholders that are contingent upon achievement of certain designations following FDA review. If the optimal CVR milestone is realized, the combined cash and CVR consideration payable in the proposed transaction will be $125 per share, or approximately $1.5 billion in the aggregate. If eluxadoline receives FDA approval and is not scheduled as a controlled drug by the DEA, holders of the CVR will receive $30 per share or approximately $360 million in the aggregate. If eluxadoline is designated as a Schedule 4 or Schedule 5 controlled drug by the DEA, holders of the CVR will receive $10 per share (approximately $120 million in the aggregate) or $20 per share (approximately $240 million in the aggregate), respectively.

Forest expects to divest Furiex’s royalties on alogliptin and Priligy® to Royalty Pharma for a payment of approximately $415 million, which, after tax, will effectively reduce Forest’s purchase price by approximately $315 million. “Our partnership with Royalty Pharma will allow us to expand our GI franchise in a capital-efficient manner, preserving Forest capital to be deployed to areas which are core to Forest,” said Saunders.

“In partnering on this transaction, we believe Forest and Royalty Pharma have created a win-win situation,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. “Forest will acquire a company with a very exciting GI product candidate, while Royalty Pharma will acquire the non-core passive royalty assets. Our goal is to become the M&A partner of choice for pharma and biotech companies, allowing them to focus their resources on strategic assets.”

Forest expects to use cash on hand to fund the acquisition of Furiex. Forest’s planned acquisition of Furiex is expected to close in the second or third quarter of 2014 pending regulatory review and Furiex shareholder approval and is not expected to affect the timing of Actavis plc’s previously announced acquisition of Forest. Actavis has consented to Forest’s acquisition of Furiex and supports the transaction.

Covington & Burling LLP served as Forest’s legal counsel, Furiex was advised by Kirkland & Ellis LLP and Wyrick Robbins Yates & Ponton LLP, and Royalty Pharma was advised by Goodwin Procter LLP. BofA Merrill Lynch and Credit Suisse acted as financial advisors to Furiex.

Conference call details:

Forest executives will host a conference call with investors at 8:30 AM EST today to discuss the details of today’s announcement. The conference call will be webcast live on the Company’s website at www.frx.com. Please log on to the website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until May 28, 2014 by dialing (800) 839-1246 (US or Canada) or +1 (402) 220-0464 (international).

About Forest Laboratories and Its Products

Forest Laboratories (NYSE: FRX) is a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market. Forest markets a portfolio of branded drug products and develops new medicines to treat patients suffering from diseases principally in five therapeutic areas: central nervous system, cardiovascular, gastrointestinal, respiratory, and anti-infective. Forest’s strategy of acquiring product rights for development and commercialization through licensing, collaborative partnerships and targeted mergers and acquisitions allows Forest to take advantage of attractive late-stage development and commercial opportunities, thereby managing the risks inherent in drug development. In January 2014, Forest acquired Aptalis Pharmaceuticals for $2.9 billion in cash in order to gain access to its GI and Cystic Fibrosis products, including treatments for Ulcerative Proctitis, Duodenal Ulcers, H. Pylori, Anal Fissures, and Pancreatic Insufficiency. In February 2014, Forest and Actavis plc announced an agreement where Forest would be acquired for about $25 billion in cash and stock. The acquisition of Forest by Actavis is contingent upon regulatory and shareholder approvals.

Forest is headquartered in New York, NY.

About Furiex

Furiex Pharmaceuticals (NASDAQ: FURX) is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Furiex’s drug development programs are designed and driven by a core team with extensive drug development experience. Furiex collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, and four products on the market. Furiex’s mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.

Furiex is headquartered in Morrisville, NC.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late-stage biopharmaceutical products, with total assets of approximately $10 billion. Royalty Pharma owns royalty interests in 39 products including, Humira®, Lyrica®, Remicade®, Prezista®, Emtriva®, Neupogen®/Neulasta®, Januvia®/Janumet®, Tecfidera® and Imbruvica®. Royalty Pharma also funds late-stage clinical trials in exchange for royalty interests. More information on Royalty Pharma is available at www.royaltypharma.com.

Royalty Pharma is headquartered in New York, NY.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including that the transactions may not be timely completed, if at all, that prior to completion of the transactions, Furiex’s business may experience significant disruptions due to transaction-related uncertainty or other factors, the timing and the benefits of the business combination transaction, the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule, the requirement that Furiex’s security holders approve the transaction, the risk that the businesses will not be integrated successfully, the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timing of Actavis plc’s acquisition of Forest, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings and Furiex’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings. Neither Forest nor Furiex assumes any obligation to update forward-looking statements contained in this release to reflect new information or future events or developments. Each of Forest and Furiex intends such forward-looking statements to be covered by the Safe Harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and is including this statement for purposes of complying with these Safe Harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies and expectations of each of Forest and Furiex, may be identified by use of the words “believe,” “expect,” “intend,” “anticipate,” “project,” or similar expressions. Investors should not rely on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from such forward-looking statements. All forward-looking statements in this document are qualified in their entirety by this cautionary statement.

Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed acquisition of Furiex by Forest, Furiex will file a proxy statement with the SEC (the “Furiex Proxy”). Additionally, Furiex will file other relevant materials with the SEC in connection of the proposed acquisition. The Furiex Proxy and other materials that Furiex plans to file with the SEC will contain important information about Furiex, Forest, the proposed merger and related matters. The Furiex Proxy will be delivered to the security holders of Furiex. In connection with the proposed merger between Actavis, plc (“Actavis”) and Forest, Actavis has filed with the SEC a registration statement on Form S-4 that includes a preliminary joint proxy statement of Actavis and Forest that also constitutes a preliminary prospectus of Actavis (the “Forest/Actavis Proxy and Prospectus”). The registration statement is not yet effective. The definitive Forest/Actavis Proxy and Prospectus will be delivered to security holders of Actavis and Forest. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FURIEX PROXY, THE FOREST/ACTAVIS PROXY AND PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO THAT SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER. Security holders of Furiex may obtain free copies of the Furiex Proxy and other documents filed with the SEC by Forest or Furiex, without charge, from the SEC’s website (http://www.sec.gov). In addition, investors and security holders of Furiex may obtain free copies of the documents Furiex files with the SEC by directing a written request to Furiex Pharmaceuticals, Inc., 3900 Paramount Parkway, Suite 150, Morrisville, NC 27560, Attention: Investor Relations. Copies of Furiex’s filings with the SEC may also be obtained at the “Investors” section of Furiex’s internet website at www.furiex.com. Investors and security holders of Actavis and Forest may obtain free copies of the Forest/Actavis Proxy and other documents filed with the SEC by Actavis and Forest, without charge, from the SEC’s website (http://www.sec.gov). In addition, copies of the documents filed with the SEC by Actavis may be obtained free of charge on Actavis’ internet website at www.actavis.com or by contacting Actavis’ Investor Relations Department at (862) 261-7488. Copies of the documents filed with the SEC by Forest may be obtained free of charge on Forest’s internet website at www.frx.com or by contacting Forest’s Investor Relations Department at (212) 224-6713.

Participants in the Solicitation

Forest, Furiex and their directors and certain of their executive officers may be considered participants in the solicitation of proxies from the security holders of Furiex in connection with the proposed transaction between Forest and Furiex. Information about those directors and executive officers of Furiex, including their ownership of Furiex securities, is set forth in the proxy statement for Furiex’s 2014 Annual Meeting of Stockholders, which was filed with the SEC on April 11, 2014, as supplemented by other Furiex filings with the SEC. Information about the directors and executive officers of Forest is set forth in its proxy statement for its 2013 annual meeting of stockholders, which was filed with the SEC on July 8, 2013 and certain of its Current Reports on Form 8-K. Investors and security holders may obtain additional information regarding the direct and indirect interests of Furiex, Forest and their directors and executive officers in the proposed transaction by reading the applicable proxy statement and other public filings referred to above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Furiex Proxy and other relevant materials to be filed with the SEC when they become available.

Actavis, Forest, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction between Actavis and Forest. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Actavis and Forest shareholders in connection with the proposed merger will be set forth in Forest/Actavis Proxy and Prospectus when it is filed with the SEC. Information about the directors and executive officers of Forest is set forth in its proxy statement for its 2013 annual meeting of stockholders, which was filed with the SEC on July 8, 2013 and certain of its Current Reports on Form 8-K. Information about the directors and executive officers of Actavis is set forth in Actavis’ proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on March 28, 2014. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the preliminary Forest/Actavis Proxy and Prospectus and will be contained in the definitive Forest/Actavis Proxy and Prospectus and other relevant materials to be filed with the SEC when they become available.

Monday, April 28th, 2014 Uncategorized Comments Off on (FURX) Forest Laboratories Acquisition For $1.1 Billion in Cash To Solidify Lead In Gastroenterology

(UNTY) Promotes Dr. Austin H. Kutscher, Jr. and Donald Souders, Jr. Esq. to Board

CLINTON, N.J., April 25, 2014  — Unity Bancorp, Inc. (NASDAQ: UNTY), announced today that the Board of Directors appointed Dr. Austin H. Kutscher, Jr. and Donald Souders, Jr. Esq., current Directors of Unity Bank, to the Board of the Holding Company, effective as of April 24, 2014.

Dr. Kutscher is employed by Hunterdon Cardiovascular Associates and is a practicing physician at the Hunterdon Medical Center’s Department of Cardiology, Flemington, NJ.

Mr. Souders is currently serving as a Partner at the law firm of Florio, Perrucci, Steinhardt & Fader, LLC.  Mr. Souders holds a Bachelors degree from the University of Delaware and Law degree from Widener University School of Law.

“Dr. Kutscher and Mr. Souders educational experience and professional expertise will complement Unity’s already diverse Board,” said President and Chief Executive Officer, James A. Hughes.  “The Board and I are delighted to have Dr. Kutscher and Mr. Souders assist us in achieving our strategic goals.”

Unity Bancorp, Inc. is a financial service organization headquartered in Clinton, New Jersey, with approximately $961 million in assets and $768 million in deposits.  Unity Bank provides financial services to retail, corporate and small business customers through its 15 retail service centers located in Hunterdon, Middlesex, Somerset, Union and Warren counties in New Jersey and Northampton County, Pennsylvania.  For additional information about Unity visit our website at www.unitybank.com or call 800 618-BANK.

This news release contains certain forward-looking statements, either expressed or implied, which are provided to assist the reader in understanding anticipated future financial performance.  These statements involve certain risks, uncertainties, estimates and assumptions made by management, which are subject to factors beyond the company’s control and could impede its ability to achieve these goals.  These factors include general economic conditions, trends in interest rates, the ability of our borrowers to repay their loans, and results of regulatory exams, among other factors.

Friday, April 25th, 2014 Uncategorized Comments Off on (UNTY) Promotes Dr. Austin H. Kutscher, Jr. and Donald Souders, Jr. Esq. to Board

(YRCW) Driver David C. Henry Reaches Remarkable Three Million Mile Safety Record

HOLLAND, Mich., April 25, 2014  — Holland professional driver, David C. Henry, was celebrated for reaching the remarkable safety record of successfully logging three million consecutive miles without a single preventable collision.

To reach this outstanding achievement requires a lifetime commitment to safety. There are 428 active Holland professional drivers on the road who have reached the safety milestone of driving over one million consecutive miles without a preventable accident, and 146 active Holland drivers who have reached more than two million consecutive miles without a preventable accident. David is one out of seven active Holland drivers to have achieved this extraordinary three million milestone.

David has been driving professionally for 35 years, the last 28 of which he has spent with Holland. David currently makes a run from Cleveland, Ohio to South Bend, Ind. and back five days per week.

“Safety is paramount at Holland,” said Scott Ware, president of Holland. “We are tremendously proud of David and his incredible accomplishment. Having world-class professionals such as David on our team is absolutely invaluable – both for our customers and business. We thank David for his commitment to safety and his 28 years of impeccable service.”

David’s safety accomplishment was observed with a police escort to the Cleveland service center on April 15 where he was greeted by co-workers and family members. David was awarded with a trophy, ring and a commemorative 3-million-miler leather jacket. View our video coverage of the event on Holland’s YouTube channel.

“The celebration was really memorable,” said David Henry. “Holland made me feel very special that day. Mike Dzura, Cleveland service center manager, did such a great job getting everything lined up, and it was very nice for the officers to come in from out of town. My whole family was just totally blown away by all of it. I am very grateful to have had that experience.”

David’s driving record demonstrates the strong safety focus exhibited by drivers, dock workers and other professionals throughout the Holland network.

About Holland

Holland has long been recognized for delivering the most next-day service lanes in its territory and annually records one of the lowest claim ratios in the industry. Founded in Holland, Mich., in 1929, Holland provides industry leading, on-time reliability for less-than-truckload shipments in the central and southeastern United States and in eastern Canada. Holland, recognized by Logistics Management magazine with its 2013 Quest for Quality award for 28 consecutive years, was honored for performance excellence in 2013 with the Midwest/Mid-Atlantic Regional LTL Motor Carriers award and the South/South Central Regional LTL Motor Carriers award, as well as the Expedited Motor Carriers award. For more information, visit hollandregional.com. Holland is a subsidiary of YRC Worldwide.

Website: hollandregional.com
Facebook: http://www.facebook.com/hollandregional
Twitter: http://www.twitter.com/hollandregional
LinkedIn: http://www.linkedin.com/company/holland
YouTube: http://www.youtube.com/hollandregional
GooglePlus: http://www.gplus.to/hollandregional

CONTACT: Media Contact:
         Suzanne Dawson
         LAK Public Relations, Inc.
         212-329-1420
         sdawson@lakpr.com
Friday, April 25th, 2014 Uncategorized Comments Off on (YRCW) Driver David C. Henry Reaches Remarkable Three Million Mile Safety Record

(WTSL) to Exit Arden B Business

The Wet Seal, Inc. (Nasdaq:WTSL), a leading specialty retailer to young women, today announced that it will begin winding down its Arden B brand. Arden B currently operates 54 mall-based stores and an e-commerce web site, www.ardenb.com. In the fiscal year ended February 1, 2014, Arden B generated net sales of $60.4 million and represented 11% of consolidated net sales.

John D. Goodman, Chief Executive Officer, stated, “This was a difficult decision that followed a comprehensive review of the business and market dynamics. We would like to thank all of our Arden B team members for their hard work and dedication to the brand, and also extend our gratitude to our loyal customers.”

31 Arden B locations will transition to Wet Seal Plus merchandise and the remaining 23 locations will transition from Arden B to Wet Seal merchandise. Where permissible, Arden B locations will be refreshed with either Wet Seal or Wet Seal Plus signage. The Company expects to complete this conversion by the start of the back-to-school selling season in late July.

Through lease expirations and the exercise of early termination provisions, the Company will close 15 Arden B locations through the remainder of fiscal 2014 and 16 Arden B locations in fiscal 2015. For the interim period while Arden B locations remain open, the stores will offer Wet Seal or Wet Seal Plus merchandise, as noted above.

Effective immediately, the Wet Seal merchandising organization assumes responsibility for Arden B stores. The buying, planning and allocation team for Arden B will be impacted by the wind-down. The release of some team members and reduction in other expenses will result in annualized pre-tax cost savings of approximately $1.3 million beginning in the second quarter of fiscal 2014.

Mr. Goodman concluded, “With this process underway, our management team and Board of Directors will be focusing greater attention on our sweeping strategic initiatives, and this change positions us to take advantage of opportunities for growth within the Wet Seal brand. We are making progress against our strategic plan to enhance Wet Seal’s product, merchandising, customer engagement and overall store performance, as well as drive growth in our e-commerce business. Importantly, our transition strategy for Arden B accelerates our opportunity to expand in the growing junior plus market.”

The Company expects to incur approximately $0.1 million of charges for severance costs in the first quarter of fiscal 2014 and approximately $0.3 million of charges for store employee retention programs in the second and third quarters of fiscal 2014. The Company also anticipates non-cash asset impairment charges of up to approximately $3 million in the first quarter of fiscal 2014 pertaining to Arden B store assets. In addition, the exercise of early lease termination provisions in fiscal years 2014 and 2015 is expected to result in approximately $0.5 million of payments related to unamortized tenant allowances. Wet Seal intends to negotiate with landlords and pursue other alternatives to expedite the transition and exit of the remaining 23 Arden B locations where leases do not expire prior to its fiscal 2015 year end.

First Quarter Financial Guidance and Conference Call Details

The Company reiterated its previously announced financial guidance for the first quarter of fiscal 2014, which includes net loss per diluted share, before non-cash asset impairments and charges related to the wind-down of Arden B operations, of between $0.16 and $0.19, and comparable store sales, including e-commerce, in the negative mid- to high- teens.

The Company will hold a conference call to discuss first quarter fiscal 2014 financial results on Tuesday, May 27, 2014, at 1:30 p.m. Pacific Time. The call will be hosted by John D. Goodman, Chief Executive Officer, and Steve Benrubi, Executive Vice President and Chief Financial Officer.

To participate in the call, please dial (877) 407-3982 or (201) 493-6780. A broadcast of the call will also be available on the Company’s web site at www.wetsealinc.com. A replay of the call will be available through June 10, 2014. To access the replay, please dial (877) 870-5176 or (858) 384-5517 and provide pin number 13580729.

About The Wet Seal, Inc.

Headquartered in Foothill Ranch, California, The Wet Seal, Inc. is a leading specialty retailer of fashionable and contemporary apparel and accessory items. As of April 25, 2014, the Company operated a total of 532 stores in 47 states and Puerto Rico, including 478 Wet Seal stores and 54 Arden B stores. The Company’s products can also be purchased online at www.wetseal.com or www.ardenb.com. For more Company information, visit www.wetsealinc.com.

Safe Harbor

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company’s Arden B exit plans described herein as well as the intent, belief, plans or expectations of the Company or its management. All forward-looking statements made by the Company involve material risks and uncertainties and are subject to change based on factors beyond the Company’s control. Accordingly, the Company’s future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Such factors include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission. The Company will not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

Friday, April 25th, 2014 Uncategorized Comments Off on (WTSL) to Exit Arden B Business

(OTEX) & Ontario Announce Tech Job Creation Initiative

OpenText Announces Plans for New Worldwide Customer Briefing Center in Toronto; Expansion Plans for Waterloo

WATERLOO, Ontario, April 25, 2014  — Ontario Premier Kathleen Wynne and Mark Barrenechea, President and CEO of OpenText™ (NASDAQ: OTEX, TSX: OTC), the global leader in Enterprise Information Management (EIM) and Canada’s largest software company, announced today an agreement to create 1,200 jobs across the province over the next seven years, nearly doubling the Company’s Canadian workforce.

“At OpenText, our employees are our most valuable assets, and our commitment today validates the strength of the technology talent pool in Ontario,” said Barrenechea. “We are an Ontario-grown global company and we chose to invest here because of the highly educated workforce, our strong university partnerships in R&D, as well as the province’s robust and innovative start-up communities.”

OpenText and the Province of Ontario have signed a seven-year agreement that will see OpenText invest up to $2 billion in job creation. Under the terms of the agreement, OpenText will add up to 1,200 high tech jobs within the next seven years. The Province of Ontario will provide OpenText up to $120 million in support of the initiative.

“I am thrilled that OpenText, a made-in-Ontario success story, decided to carry out this expansion here,” said Kathleen Wynne, Premier of Ontario. “We are proud to partner with OpenText to help create good jobs in Ontario and build a brighter future for our province.”

More than 30 percent of the jobs created will be in R&D and 10 percent will be for youth in the province, those 29 years old and under.

“Ontario’s technology sector has established a tremendous momentum that has positioned the province front-and-centre as business leaders around the world make decisions about where to invest and grow,” said Dr. Eric Hoskins, Minister of Economic Development, Trade and Employment. “OpenText’s decision to invest and create jobs here in Ontario is a vote of confidence in our tech sector and in the talented people who help it thrive and grow. This is about advanced technology, but it’s also about everyday people—ensuring families have stable employment and young people in school have prospects when they graduate.”

In addition to expanding OpenText’s footprint at its corporate headquarters in Waterloo and its Ottawa offices, the Company also announced the future site of its worldwide customer briefing centre and offices in the heart of downtown Toronto. OpenText Ontario offices include worldwide headquarters in Waterloo, operations in Richmond Hill, worldwide customer briefing center in Toronto (to open late summer), Ottawa, Peterborough, and Kingston for research and development. Nation-wide, offices include Montreal and Calgary.

“This initiative is about immediate and long-term job creation at OpenText, enabling our Canadian employees to compete on the world stage,” said Barrenechea. “A strong OpenText means a stronger Ontario.

OpenText is deeply committed to supporting technology innovation and has undertaken a number of initiatives within the last six months intended to directly seed technology entrepreneurship and innovation in Canada:

  • February 28, 2014: OpenText sponsors the Canadian Open Data Experience (CODE) national appathon;
  • February 11, 2014: OpenText announces it is a founding partner in the Open Data Institute;
  • January 21, 2014: OpenText announces it is the lead industry sponsor in a newly created $217 million VCAP ‘fund of funds’ that will invest in high-potential venture capital fund managers across Canada to seed innovation, along with the federal and provincial governments;
  • January 21, 2014: OpenText announces it expects to close in the next six months with its financial partners, a $100 million OpenText Enterprise Applications Venture Fund (OTEAF) to infuse funding directly into creative app development;
  • November 2013: OpenText announced its own AppWorks developer platform to dramatically accelerate the time to market for enterprise-grade applications. Entrepreneurs can get on board at: https://developer.opentext.com

Learn more about OpenText EIM:

About OpenText
OpenText provides Enterprise Information Management software that helps companies of all sizes and industries to manage, secure and leverage their unstructured business information, either in their data center or in the cloud. Nearly 100,000 companies already use OpenText solutions to unleash the power of their information. To learn more about OpenText (NASDAQ: OTEX; TSX: OTC), please visit: www.opentext.com.

Certain statements in this press release may contain words considered forward-looking statements or information under applicable securities laws. These statements are based on OpenText’s current expectations, estimates, forecasts and projections about the operating environment, economies and markets in which the company operates. These statements are subject to important assumptions, risks and uncertainties that are difficult to predict, and the actual outcome may be materially different. OpenText’s assumptions, although considered reasonable by the company at the date of this press release, may prove to be inaccurate and consequently its actual results could differ materially from the expectations set out herein. For additional information with respect to risks and other factors which could occur, see OpenText’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other securities filings with the SEC and other securities regulators. Unless otherwise required by applicable securities laws, OpenText disclaims any intention or obligations to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Copyright ©2014 Open Text Corporation. OpenText is a trademark or registered trademark of Open Text SA and/or Open Text ULC. The list of trademarks is not exhaustive of other trademarks, registered trademarks, product names, company names, brands and service names mentioned herein are property of Open Text SA or other respective owners. All rights reserved. For more information, visit: http://www.opentext.com/2/global/site-copyright.html_SKU.

Friday, April 25th, 2014 Uncategorized Comments Off on (OTEX) & Ontario Announce Tech Job Creation Initiative

(BLDP) Closes Strategic Intellectual Property Transaction with United Technologies Corp.

  • Acquisition of United Technologies fuel cell IP portfolio
  • Strategic alliance with United Technologies focused on IP licensing

VANCOUVER, April 24, 2014 – Ballard Power Systems (NASDAQ: BLDP)( TSX: BLD) today announced that it has acquired the transportation- and stationary-related fuel cell intellectual property (IP) assets of United Technologies Corporation (“UTC”, NYSE: UTX). These assets consist of approximately 800 patents and patent applications, as well as patent licenses, invention disclosures and know-how primarily related to Proton Exchange Membrane (PEM) fuel cell technology.

John Sheridan, Ballard President and CEO said, “We believe that this acquisition gives Ballard a commanding position in strategic fuel cell IP, strengthening our ability to grow shareholder value. Further, our new alliance with United Technologies will bolster Ballard’s execution capabilities, particularly in the generation of IP licensing revenue.”

In addition to incremental IP licensing revenue opportunities, the acquired intellectual property assets will support other key elements of Ballard’s corporate strategy: engineering service capabilities will be expanded in both automotive and non-automotive markets; and fuel cell product sales will be accelerated through product development initiatives in areas such as durability and balance of plant simplification.

As consideration for the patents and patent applications as well as patent licenses, invention disclosures and know-how, UTC has received 5.1 million Ballard common shares, $2 million in cash, a grant back license to use the patent portfolio in UTC’s existing businesses and a royalty on Ballard’s future IP licensing income generated from the combined IP portfolio.

In connection with the transaction, Ballard and United Technologies have formed a strategic alliance led by a joint Advisory Council. The Advisory Council will focus on licensing and other commercial market opportunities arising from the combination of the acquired UTC portfolio with Ballard’s extensive intellectual property.

Kelly Romano, Vice President of UTC’s Innovation Business Development group added, “With over 50 years of leading edge technology development, UTC’s fuel cell IP portfolio is widely recognized as one of the foundational and pioneering technology assets in the space. We are excited to announce today’s alliance with Ballard to continue the development and commercialization of these valuable assets.”

About Ballard Power Systems
Ballard Power Systems (NASDAQ: BLDP)(TSX: BLD) provides clean energy fuel cell products enabling optimized power systems for a range of applications. Products deliver incomparable performance, durability and versatility. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning anticipated shipments, product attributes and corresponding value propositions for our customers. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Guy McAree +1.604.412.7919, media@ballard.com or investors@ballard.com

Thursday, April 24th, 2014 Uncategorized Comments Off on (BLDP) Closes Strategic Intellectual Property Transaction with United Technologies Corp.

(TQNT) to Participate at Upcoming Investor Conferences

TriQuint Semiconductor, Inc. (NASDAQ: TQNT), a leading RF solutions supplier and technology innovator, announced that the company is scheduled to present at the following investor conferences during the quarter:

  • 6th Annual Technology Forum hosted by D.A. Davidson
    May 28th 2014 at The Grand Hyatt in New York, NY
    * Given the meeting format of this conference it will not be webcast
  • 11th Annual Craig-Hallum Institutional Investor Conference
    May 28th 2014 at The Minneapolis Marriott City Center Hotel in Minneapolis, MN
    * Given the meeting format of this conference it will not be webcast
  • The Bank of America / Merrill Lynch 2014 Global Technology Conference
    June 4th 2014 at The Ritz Carlton Hotel in San Francisco, CA

A link to the live audio webcast of the Bank of America / Merrill Lynch conference and the presentation materials will be available on the investor section of the TriQuint website at http://invest.triquint.com/.

FACTS ABOUT TRIQUINT

Founded in 1985, TriQuint Semiconductor (NASDAQ: TQNT) is a leading global provider of innovative RF solutions and foundry services for the world’s top communications, defense and aerospace companies. People and organizations around the world need real-time, all-the-time connections; TriQuint products help reduce the cost and increase the performance of connected mobile devices and the networks that deliver critical voice, data and video communications. With the industry’s broadest technology portfolio, recognized R&D leadership, and expertise in high-volume manufacturing, TriQuint creates standard and custom products using gallium arsenide (GaAs), gallium nitride (GaN), surface acoustic wave (SAW) and bulk acoustic wave (BAW) technologies. The company has ISO9001-certified manufacturing facilities in the U.S., production in Costa Rica, and design centers in North America and Germany. For more information, visit www.triquint.com.

Thursday, April 24th, 2014 Uncategorized Comments Off on (TQNT) to Participate at Upcoming Investor Conferences

(SYRG) Mid-Year Proved Reserves Increase 43%

PLATTEVILLE, CO–(April 24, 2014) – Synergy Resources Corporation (NYSE MKT: SYRG), a U.S. oil and gas exploration and production company focused in the Denver-Julesburg Basin, announces that its mid-year proved reserve evaluation for the six months ending 2/28/2014 increased to 19.7mm/BOE compared to 13.8mm/BOE for the fiscal year end 8/31/2013 and the PV10 value of the proved reserves increased to $326 million from $236 million. Proved developed producing and proved developed non-producing (behind pipe) assets accounted for two thirds of the value of the reserves while the remaining third of the value is proved undeveloped reserves.

William E. Scaff, Jr. co-CEO of Synergy commented, “The increase in our reserves is largely a result of the success of our operated horizontal drilling program with our first 11 horizontal wells being included as proved developed producing assets. Our plans call for another 20-25 horizontal wells to be included in the reserve report for our fiscal year ending August 31st, 2014. We continue to work with Ryder Scott Company, our third party reserve engineers, to account for increased density of horizontal Niobrara and Codell wells in the Wattenberg Field.”

About Synergy Resources Corporation
Synergy Resources Corporation is a domestic oil and natural gas exploration and production company. Synergy’s core area of operations is in the Denver-Julesburg Basin, which encompasses Colorado, Wyoming, Kansas, and Nebraska. The Wattenberg field in the D-J Basin ranks as one of the most productive fields in the U.S. The company’s corporate offices are located in Platteville, Colorado. More company news and information about Synergy Resources is available at www.syrginfo.com.

Important Cautions Regarding Forward Looking Statements

This press release may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates”, “should”, “likely” or similar expressions, indicates a forward-looking statement. These statements are subject to risk and uncertainties and are based on the beliefs and assumptions of management, and information currently available to management. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. Certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. The identification in this press release of factors that may affect the company’s future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Factors that could cause the company’s actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: the success of the company’s exploration and development efforts; the price of oil and gas; worldwide economic situation; change in interest rates or inflation; willingness and ability of third parties to honor their contractual commitments; the company’s ability to raise additional capital, as it may be affected by current conditions in the stock market and competition in the oil and gas industry for risk capital; the company’s capital costs, which may be affected by delays or cost overruns; costs of production; environmental and other regulations, as the same presently exist or may later be amended; the company’s ability to identify, finance and integrate any future acquisitions; and the volatility of the company’s stock price.

Investor Relations Contact:
Jon Kruljac
Synergy Resources Corporation
jkruljac@syrginfo.com
Tel (303) 840-8166

Company Contact:
Rhonda Sandquist
Synergy Resources Corporation
rsandquist@syrginfo.com
Tel (970) 737-1073

Thursday, April 24th, 2014 Uncategorized Comments Off on (SYRG) Mid-Year Proved Reserves Increase 43%

(UTEK) Corporate Culture Of Safety Expands To New Facilities, Health And Safety Award Received

14th Workers’ Compensation Carrier Award Positions Ultratech as a Global Industry Benchmark

SAN JOSE, Calif., April 24, 2014 /PRNewswire/ — Ultratech, Inc. (Nasdaq: UTEK), a leading supplier of lithography, laser-processing and inspection systems used to manufacture semiconductor devices and high-brightness LEDs (HB-LEDs), recently received its 14th  safety recognition award from its workers’ compensation carrier for its exemplary health and safety record.  The award, presented jointly by Ultratech’s broker Wells Fargo Insurance Services USA, Inc., and Berkley Technology Underwriters, a Berkley Company, acknowledges Ultratech’s efforts to incorporate safety as part of the company’s corporate culture.  This recognition confirms the successful extension of Ultratech’s ongoing, company-wide commitment to its employees’ welfare to its new facilities in Waltham, Mass. and Singapore.  Marking its 14th health and safety award, Ultratech has maintained its excellent safety record.

Matthew Mueller, President, Berkley Technology Underwriters, a Berkley Company, stated, “The company was founded in 1967 and is one of the nation’s premier commercial lines property casualty insurance providers.  Like Ultratech, it is our long-time industry experience and specialized knowledge that differentiates us from other companies.  We are proud to be Ultratech’s partner and are committed to supporting all of its global employees in maintaining a safe and thriving work environment.”

“In all areas of its organization, Ultratech’s commitment to safety and overall employee well-being is part of its value-driven culture,” stated Sam Elliot, regional managing director for Wells Fargo Insurance Services USA, Inc.’s West region.

“Starting with our San Jose headquarters and including our manufacturing facility in Singapore and Cambridge Nanotech business in Waltham, Mass., Ultratech has successfully extended its culture of safety to all of its locations.  Safety is built into everything that we do and we strive to make continuous improvements to an already enviable record,” noted Arthur W. Zafiropoulo, Ultratech’s Chairman and CEO.  “I am proud to receive this award and direct the accolades to our employees who work conscientiously to make safety and quality synonymous with Ultratech.”

“Our success is due both to the leadership of our managers and a workforce that focuses on making safety at Ultratech a top priority throughout our worldwide operations,” explained Bruce Wright, Ultratech’s Senior Vice President and CFO.  “Not only are we rewarded with a safe and productive working environment, but Ultratech also realizes important savings in the cost of doing business, as well as excellent insurance rates.”

Safe Harbor
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipates,” “expects,” “remains,” “thinks,” “intends,” “believes,” “estimates,” and similar expressions and include management’s current expectation of its longer term prospects for success. These forward-looking statements are based on our current expectations, estimates, assumptions and projections about our business and industry, and the markets and customers we serve, and they are subject to numerous risks and uncertainties that may cause these forward-looking statements to be inaccurate. Such risks and uncertainties include the timing and possible delays, deferrals and cancellations of orders by customers; quarterly revenue fluctuations; industry and sector cyclicality, instability and unpredictability; market demand for consumer devices utilizing semiconductors produced by our clients; our ability to manage costs; new product introductions, market acceptance of new products and enhanced versions of our existing products; reliability and technical acceptance of our products; our lengthy sales cycles, and the timing of system installations and acceptances; lengthy and costly development cycles for laser-processing and lithography technologies and applications; competition and consolidation in the markets we serve; improvements, including in cost and technical features, of competitors’ products; rapid technological change; pricing pressures and product discounts; our ability to collect receivables; customer and product concentration and lack of product revenue diversification; inventory obsolescence; general economic, financial market and political conditions and other factors outside of our control; domestic and international tax policies; cybersecurity threats in the United States and globally that could impact our industry, customers, and technologies; and other factors described in our SEC reports including our Annual Report on Form 10-K filed for the year ended December 31, 2013, and our Quarterly Report on Form 10-Q for the three months ended September 28, 2013. Due to these and other factors, the statements, historical results and percentage relationships set forth herein are not necessarily indicative of the results of operations for any future period. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

About Ultratech: Ultratech, Inc. (Nasdaq: UTEK) designs, builds and markets manufacturing systems for the global technology industry. Founded in 1979, Ultratech serves three core markets: front-end semiconductor, back-end semiconductor, and nanotechnology. The company is the leading supplier of lithography products for bump packaging of integrated circuits and high-brightness LEDs. Ultratech is also the market leader and pioneer of laser spike anneal technology for the production of advanced semiconductor devices. In addition, the company offers solutions leveraging its proprietary coherent gradient sensing (CGS) technology to the semiconductor wafer inspection market and provides atomic layer deposition (ALD) tools to leading research organizations, including academic and industrial institutions. Visit Ultratech online at: www.ultratech.com.

Thursday, April 24th, 2014 Uncategorized Comments Off on (UTEK) Corporate Culture Of Safety Expands To New Facilities, Health And Safety Award Received